Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it will charge the same in the UK for new schizophrenia drug Cobenfy as in the ...
Bristol Myers Squibb will pay T-cell engager company Janux Therapeutics $50 million in the near term as part of a collaboration to work on a novel tumor-activated therapeutic. The resulting candidate ...
Bristol Myers Squibb added a big name to its executive roster with the appointment of Harald Hampel, M.D., Ph.D. as its new SVP and worldwide head of medical affairs, neuroscience. Hampel comes to BMS ...
The impending merger between Bristol-Myers Squibb (BMS) and Medarex marks the end of an era. Medarex is one of the last independent public biotech companies that built their businesses around ...
4,823,214 reviews on ConsumerAffairs are verified. We require contact information to ensure our reviewers are real. We use intelligent software that helps us maintain the integrity of reviews. Our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results